Drug Trial Radar · NCT06712654
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
168
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Feb 28, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- R1 TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Alebund Pharmaceuticals
- First posted
- Dec 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to characterize the safety, tolerability, and efficacy of AP306 at fixed doses in adults with hyperphosphatemia receiving maintenance hemodialysis.
Conditions
- Hyperphosphatemia
- Chronic Kidney Disease Requiring Chronic Dialysis
- End Stage Renal Disease on Dialysis
Interventions
AP306 75 mg BIDDrug
AP306 75 mg by mouth, twice daily (150 mg/day). Placebo given once daily. Treatment given daily for 8 weeks.
AP306 125 mg BIDDrug
AP306 125 mg by mouth, twice daily (250 mg/day). Placebo given once daily. Treatment given daily for 8 weeks.
AP306 150 mg BIDDrug
AP306 150 mg by mouth, twice daily (300 mg/day). Placebo given once daily. Treatment given daily for 8 weeks.
AP306 75 mg TIDDrug
AP306 75 mg by mouth, three times daily (225 mg/day). Treatment given daily for 8 weeks.
AP306 100 mg TIDDrug
AP306 100 mg by mouth, three times daily (300 mg/day). Treatment given daily for 8 weeks.
AP306 125 mg TIDDrug
AP306 125 mg by mouth, three times daily (375 mg/day). Treatment given daily for 8 weeks.
PlaceboDrug
Placebo given by mouth, three times daily. Treatment given daily for 8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To investigate the ability of AP306 at different fixed doses to lower serum phosphate in participants with hyperphosphatemia receiving maintenance hemodialysisTime frame: 8 weeks
Locations
31 sites in 2 countries. Site status is shown where the registry gives one.
Apogee Clinical Research, LLC
Huntsville, Alabama · Recruiting
California Institute of Renal Research
Chula Vista, California · Recruiting
Academic Medical Research Institute
Los Angeles, California · Recruiting
North America Research Institute
San Dimas, California · Recruiting
Colorado Kidney Care
Denver, Colorado · Recruiting
DaVita Clinical Research
Middlebury, Connecticut · Recruiting
PACT Kidney Care
Orange, Connecticut · Recruiting
US Renal Care - Fort Myers South
Fort Myers, Florida · Recruiting
Nephrology & Hypertension Specialists
Dalton, Georgia · Recruiting
St. Clair Nephrology Research
Shelby, Michigan · Recruiting
DaVita Clinical Research Edina
Edina, Minnesota · Recruiting
Johnson County Clinical Trials
Kansas City, Missouri · Recruiting
DaVita Clinical Research
Las Vegas, Nevada · Recruiting
R1 Therapeutics Clinical Trial Site
Albuquerque, New Mexico · Recruiting
NY Kidney & Hypertension Medicine
Ridgewood, New York · Recruiting
US Renal Care - Alexis
Toledo, Ohio · Recruiting
Sunbeam Research
Greenville, Texas · Recruiting
DaVita Clinical Research
Houston, Texas · Recruiting
Gamma Medical Research
McAllen, Texas · Recruiting
US Renal Care - South San Antonio
San Antonio, Texas · Recruiting
US Renal Care - Westover Hills
San Antonio, Texas · Recruiting
DaVita Clinical Research San Antonio
San Antonio, Texas · Recruiting
US Renal Care
Waxahachie, Texas · Recruiting
DaVita Clinical Research Norfolk
Norfolk, Virginia · Recruiting
Peking University First Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Zhengzhou University-First Affiliated Hospital
Zhengzhou, Henan, China · Recruiting
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China · Recruiting
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China · Recruiting
Shanghai Jiao Tong University School of Medicine, Renji Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.